Skip to main content
Clinical Trials/CTRI/2025/03/082592
CTRI/2025/03/082592Not yet recruitingNot Applicable

A prospective observational study on effect of dapagliflozin on body composition In type 2 diabetes mellitus patients inadequately controlled with metformin at SMS hospital, jaipur during 2024-2026.

Bhavya Raj1 site in 1 country60 target enrollmentStarted: February 4, 2025Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
60
Locations
1
Primary Endpoint
1. The proportion of patients on dapagliflozin showing reduction in total body fat ,total body lean mass, total body fat percentage using DEXA Scan.

Study Overview

Brief Summary

Adipose tissue contributes to insulin resistance through inflammatory mechanisms, highlighting the importance of managing body composition in type 2 diabetes mellitus (T2DM). Key risk factors for T2DM include obesity, high-caloric diets, and sedentary lifestyles, which have led to a global increase in the disease. While many drugs improve the quality of life for T2DM patients, addressing adiposity is crucial for effective treatment. This study will give us a better understanding about the effect of dapagliflozin on body composition in T2DM patients inadequately controlled on metformin.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18.00 Year(s) to 99.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • All patients of more than 18 years and of either sex whose HbA1C levels are more than 7.5 after at least 3 months of treatment with metformin.
  • Patients giving consent for the study.

Exclusion Criteria

  • Patients whose BMI less than 20 and BMI more than 35 (morbid obese)
  • Patients with any other comorbidities like dyslipidemia, hypertension, cardiac disorders etc.
  • Patients with evidence of micro or macrovascular complications.

Outcomes

Primary Outcomes

1. The proportion of patients on dapagliflozin showing reduction in total body fat ,total body lean mass, total body fat percentage using DEXA Scan.

Time Frame: 1. 0 month. | 2. 3 months. | 3. 6 months.

2. The proportion of patients showing changes in VAT and SAT Score using MRI

Time Frame: 1. 0 month. | 2. 3 months. | 3. 6 months.

3. The proportion of patients showing changes in physical parameters like BMI, body weight and waist circumference

Time Frame: 1. 0 month. | 2. 3 months. | 3. 6 months.

Secondary Outcomes

  • 1. The proportion of patients showing improvement in glycemic control using HbA1C and FBG in the study population.(2. The proportion of patients showing improvement on insulin resistance by monitoring adiponectin level.)

Investigators

Sponsor
Bhavya Raj
Sponsor Class
Other [self]

Study Sites (1)

Loading locations...

Similar Trials